论文部分内容阅读
目的 探讨急性髓细胞系白血病 (AML)患者可溶性耐药相关钙结合蛋白基因 (sorcin)和多药耐药基因 (mdr1)的相关性表达及其与临床耐药和疗效的关系。方法 Northernblot检测K5 6 2 /A0 2细胞株sorcin和mdr1基因的表达 ,用半定量逆转录聚合酶链反应 (RT PCR)检测 6 5例AML患者、2 7例非白血病患者和健康人的sorcin基因和mdr1基因表达 ,并分析sorcin基因和mdr1基因表达的相关性及其临床意义。结果 AML患者中 ,sorcin和mdr1基因表达明显高于正常对照组 ,差异有非常显著性 (P <0 .0 0 1) ;在AML和对照组中 ,sorcin和mdr1基因的表达有较好的相关性 ;sorcin和mdr1基因的共表达与AML患者的临床耐药和预后具有较高的符合率。Sorcin+ 和mdr1+ 组患者临床耐药发生率为 92 .9% ,完全缓解 (CR)率为 7.1% ;sorcin-和mdr1-组患者临床耐药发生率为 8.6 % ,CR率为91.4 %。结论 白血病患者的sorcin和mdr1基因共表达与其临床耐药和预后密切相关 ,可作为检测临床耐药和判断预后的有效手段之一。
Objective To investigate the expression of sorcin and mdr1 gene in patients with acute myeloid leukemia (AML) and their relationship with clinical resistance and efficacy. Methods The expression of sorcin and mdr1 gene in K562 / A02 cell line was detected by Northern blot. The sorcin gene in 65 AML patients, 27 non-leukemia patients and healthy individuals were detected by semi-quantitative reverse transcription polymerase chain reaction (RT PCR) And mdr1 gene expression, and analysis sorcin gene and mdr1 gene expression and its clinical significance. Results The expression of sorcin and mdr1 in AML patients was significantly higher than that in the normal control group (P <0.01). The expression of sorcin and mdr1 gene in AML and control groups was correlated well The co-expression of sorcin and mdr1 genes has a high coincidence rate with the clinical drug resistance and prognosis of AML patients. The rate of clinical drug resistance was 92.9% in patients with Sorcin + and mdr1 +, and 7.1% in complete remission (CR). The rate of clinical drug resistance in sorcin- and mdr1- patients was 8.6% and the CR rate was 91.4%. Conclusion The coexpression of sorcin and mdr1 gene in patients with leukemia is closely related to their clinical resistance and prognosis, which may be used as an effective measure to detect clinical resistance and prognosis.